Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Share-based Compensation (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Share-based Compensation for 11 consecutive years, with $123.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 15.0% to $123.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $510.9 million through Dec 2025, up 15.68% year-over-year, with the annual reading at $510.9 million for FY2025, 15.68% up from the prior year.
  • Share-based Compensation for Q4 2025 was $123.8 million at BeOne Medicines, down from $140.8 million in the prior quarter.
  • The five-year high for Share-based Compensation was $150.8 million in Q2 2025, with the low at $45.8 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $93.2 million, with a median of $90.8 million recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 43.03% in 2022, then grew 7.68% in 2025.
  • Over 5 years, Share-based Compensation stood at $63.0 million in 2021, then increased by 23.99% to $78.1 million in 2022, then increased by 18.94% to $92.9 million in 2023, then grew by 15.82% to $107.6 million in 2024, then rose by 15.0% to $123.8 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $123.8 million, $140.8 million, and $150.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.